Advanced Laser & Energy Technologies
A gentle, non-ablative fractional laser designed for preventative skin health and early signs of ageing — delivering glowing, refined skin with minimal downtime. Most patients need 3–4 sessions, with 1–2 days of downtime, and results show in 1–2 weeks. Dr. Anna Lisniak, specialist dermatologist, treats patients at Fayy Health, One Central, Dubai.
Book a Consultation
Sessions Needed
3–4 sessions
Downtime
1–2 days
Results Visible
1–2 weeks
Results Last
6–12 months
What It Treats
MOXI is one of the gentlest fractional lasers available, making it ideal for patients seeking preventative skin maintenance or those who can't accommodate the longer downtime of more intensive resurfacing treatments.
Before Your Treatment
A little preparation goes a long way toward a comfortable session and optimal results. Dr. Anna will go over a personalised pre-care plan during your consultation — but here's what to generally expect.
After Your Treatment
MOXI is gentle: expect redness for a day and a slightly rough, darker texture for a few days while the treated skin flakes away. Here's a general idea of what to expect.
Skin may feel warm and appear lightly flushed, similar to a mild sunburn.
Skin may feel slightly rough or have a sandpaper-like texture as it begins to renew.
Very fine, light flaking may occur — much milder than more aggressive resurfacing lasers.
Fresh, brighter skin is revealed, with continued improvement in tone and texture.
Aftercare
Following the aftercare plan closely is one of the biggest factors in how well your skin heals and how long your results last. Dr. Anna provides a full written aftercare guide after every session.
Risks & Suitability
MOXI is a light, non-ablative laser, so side effects are usually mild and short.
Related: HALO laser · HALO, BBL and Pico Genesis compared
Usually settles within 1–2 days.
Fine dark dots that shed within a week.
Antiviral tablets may be advised if you get cold sores.
More likely with sun exposure or on darker skin.
Pregnancy; a recent tan or sunburn; isotretinoin (Roaccutane) taken in the last 6 months; an active cold sore or skin infection in the area; a history of keloid scars; medicines that make skin sensitive to light. Tell Dr. Anna about any of these before booking.
Good to Know
MOXI is a gentler, non-ablative laser with less downtime, making it ideal for preventative care or those wanting minimal disruption. HALO combines ablative and non-ablative technology for more intensive resurfacing.
Yes, MOXI is specifically designed to be safer across a broader range of skin tones compared to more aggressive lasers, though Dr. Anna will still tailor settings to your specific skin type.
Most patients benefit from a series of 3–4 sessions spaced about 4 weeks apart for cumulative improvement, followed by periodic maintenance.
Generally yes, once any initial redness has subsided, though stick to clean, non-comedogenic products during the healing period.
Yes — MOXI is often chosen specifically as a preventative, maintenance-style treatment for patients wanting to stay ahead of visible ageing with minimal downtime.
Large pores are mostly set by genetics and oil production, so they can be made less visible but not removed. Gentle fractional laser such as MOXI, RF microneedling such as Morpheus8, and a skincare routine with a retinoid all help. Dr. Anna chooses between them based on your skin type and downtime.
The price depends on the area treated and the number of sessions in your plan, so it is set after Dr. Anna has assessed your skin and agreed a plan with you. You receive a personal quote at the consultation, before any treatment starts. Message the clinic on WhatsApp (+971 50 408 9909) to book a consultation.
Book a consultation with Dr. Anna to see if MOXI is right for you.
This information is provided for general educational purposes and does not constitute medical advice. Individual results and suitability vary — a personalised assessment with Dr. Anna is required before any treatment.
Dr. Anna Lisniak, Specialist Dermatologist (DHA licence 77231337-006). Last updated 8 November 2026.